Biological Spill Clean-up
It is important for laboratory personnel to have the appropriate materials and follow proper procedures for the clean up of spills involving biological hazards.
Exposure to a Potentially Infectious Material
- Stop work and immediately wash or flush the exposed area with soap and water for 10 minutes. If exposure is to the eyes, flush eyes (holding open) using the eyewash station for 10 minutes.
- Follow steps outlined in the UofSC Workers’ Compensation Guidance for Work Related Accidents or Injuries.
- Complete and submit the UofSC Laboratory Incident Report Form [docx] to the Biological Safety Officer (BSO) at firstname.lastname@example.org and the Institutional Biosafety Committee (IBC) at email@example.com (within 3 days of the incident).
Note: The exposed employee and/or their supervisor should provide the healthcare professional
evaluating the exposure incident with a description of the job duties relevant to
the exposure incident, route(s) of exposure, circumstances of exposure, biological
agent or hazard involved in the incident (e.g. HIV+ blood, Vibrio parahaemolyticus,
lentiviral vector), and relevant medical records.
Authorized Treatment Facilities
You must receive medical treatment for work related injuries at the medical facility designated for your campus:
UofSC Columbia & School of Medicine
Center for Health and Well-Being
1401 Devine Street
Columbia, SC 29208
See the UofSC Workers’ Compensation website for additional guidance.
Reporting Requirements for Recombinant DNA Research
The NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) states that "...any significant problems, violations of the NIH Guidelines, or any significant research-related accidents and illnesses" must be reported to the NIH Office of Science Policy (OSP) within 30 days. Certain types of accidents must be reported on a more expedited basis. Spills or accidents in BL2 laboratories resulting in an overt exposure must be immediately reported to the NIH OSP.
Any spill or accident involving recombinant DNA research of the nature described above or that otherwise leads to personal injury or illness or to a breach of containment must be reported to the NIH OSP. These kinds of events might include skin punctures with needles containing recombinant DNA, the escape or improper disposition of a transgenic animal, or spills of high-risk recombinant materials occurring outside of a biosafety cabinet. Failure to adhere to the containment and biosafety practices articulated in the NIH Guidelines must also be reported to the NIH OSP. Minor spills of low-risk agents not involving a breach of containment that were properly cleaned and decontaminated generally do not need to be reported.
All incidents must be reported by emailing a completed copy of the Template for Reporting Incidents Subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [pdf] to:
- UofSC's Biological Safety Officer (BSO) at firstname.lastname@example.org
- UofSC’s Senior Biological Safety Officer at email@example.com
- Institutional Biosafety Committee (IBC) at firstname.lastname@example.org.
For incidents in BL2 labs resulting in an overt exposure that must be immediately
reported to the NIH OSP, the Principal Investigator must submit the incident report
as soon as possible to the Senior BSO and IBC with adequate information to understand
the nature and consequences of the incident, as well as its cause. Following the initial
reporting, a more detailed report can be provided to the NIH OSP that includes the
measures taken in response to mitigate the problem and to preclude its reoccurrence.
Laboratory Accident or Injury Resources
- UofSC Lab Incident Report Form [docx]
(EH&S Use Only: Incident Investigation Form [docx])
- UofSC Workers’ Compensation Guidance for Work-Related Accidents or Injuries
- CDC Emergency Sharps Information for Bloodborne Pathogens
- OSHA Root Cause Analysis During Incident Investigation (Fact Sheet) [pdf]
- FAQs on Reporting Incidents Involving Recombinant or Synthetic Nucleic Acids